ATRC
AtriCure, Inc.
AtriCure (ATRC) Q2 2026 earnings
Published Jul 23, 2026
AI summary
- Revenue $154M, up 13% from $136M a year ago.
- Adjusted EPS $0.18 beat the $0.02 consensus by $0.16, up from −$0.02 a year ago.
- AtriCure reported second quarter 2026 revenue of $153.6 million, a 12.8% increase year over year.
- The company achieved net income of $9.0 million, compared to a net loss of $6.2 million in the prior year period.
- Growth was driven by strong performance in pain management, open ablation, and appendage management devices.
Results vs analyst consensus
Revenue
Reported
$154M
Consensus not captured before release
+13% YoY
Adjusted EPS
Reported · Adjusted earnings (loss) per diluted share
$0.18
Consensus $0.02
Beat by $0.16GAAP EPS: $0.18
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
$602M–$610M
full year 2026 revenue guidance
Next-quarter consensus not captured before release.
What to watch
- The company continues to invest in clinical trials for its BoxX-NoAF and LeAAPS programs.
Read original report
Source: AtriCure, Inc. press release · SEC Form 8-K exhibit 99.1